Reticulocyte Parameters as Early Indicators of Bone Marrow Erythropoietic Activity in Chronic B Lymphoproliferative Neoplasms

Reticulocyte parameters as early indicators of bone marrow erythropoietic activity in chronic B lymphoproliferative neoplasms

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

B Chronic Lymphocytic Leukemia Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia, B-Cell Leukemia, Lymphoid Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Newly diagnosed adult patients with Chronic B LymphoPoliferative neoplasm according to WHO classification.

Exclusion criteria

Patients received chemotherapy.

Patients with Active bleeding
Patients with recent blood transfusion (less than 2 weeks).
Patients on haematinics or vitamin B 12 therapy

Treatment and study plan

Primary outcomes

Reticulocyte count

Time frame: 1 year

Absolute peripheral blood reticulocyte count measured in patients with chronic B-cell lymphoproliferative disorders (CLPDs).

Unit of Measure: ×10⁹/L
Reticulocyte percentage

Time frame: 1 year

Percentage of reticulocytes among total red blood cells in peripheral blood of patients with CLPDs.

Unit of Measure: %
Immature reticulocyte fraction (IRF)

Time frame: 1 year

Proportion of immature reticulocytes in peripheral blood measured in patients with CLPDs.

Unit of Measure: %

Sponsors and collaborators

Lead sponsor

Huda Ahmed Abdelsabour Abdelwahab

Other

Registry information

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2027
First posted: Jan 13, 2026
Registry last updated: Jan 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed